Shares of Vitalhub Corp. (TSE:VHI - Get Free Report) have been given a consensus rating of "Buy" by the five analysts that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is C$10.05.
Several equities research analysts have recently weighed in on the company. TD Securities raised Vitalhub to a "strong-buy" rating in a research report on Monday, November 25th. Scotiabank set a C$14.00 target price on shares of Vitalhub and gave the company an "outperform" rating in a research note on Thursday. Cormark lifted their price objective on shares of Vitalhub from C$9.50 to C$10.50 and gave the stock a "buy" rating in a report on Wednesday, October 2nd. Finally, Canaccord Genuity Group increased their price target on Vitalhub from C$12.00 to C$12.50 and gave the stock a "buy" rating in a research report on Thursday, January 16th.
Get Our Latest Report on VHI
Vitalhub Stock Performance
Shares of TSE:VHI traded up C$0.25 during trading on Thursday, reaching C$11.73. 68,152 shares of the stock were exchanged, compared to its average volume of 126,380. The firm's 50-day moving average price is C$11.26 and its 200 day moving average price is C$9.63. Vitalhub has a 12-month low of C$4.36 and a 12-month high of C$12.09. The firm has a market cap of C$596.47 million, a price-to-earnings ratio of 106.64, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26.
Vitalhub Company Profile
(
Get Free ReportVitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.